Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation

Journal of Clinical Oncology

Volumn 34, Issue 19, 2016, Pages 2212-2220

  Styczynski, Jan ^a   Tridello, Gloria ^c   Gil, Lidia ^b   Ljungman, Per ^e   Hoek, Jennifer ^f   Iacobelli, Simona ^d   Ward, Katherine N ^j   Cordonnier, Catherine ^k   Einsele, Hermann ^u   Socie, Gerard ^l   Milpied, Noel ^o   Veelken, Hendrik ^g   Chevallier, Patrice ^p   Yakoub Agha, Ibrahim ^q   Maertens, Johan ^x   Blaise, Didier ^r   Cornelissen, Jan ^h   Michallet, Mauricette ^s   Daguindau, Etienne ^t   Petersen, Eefke ⁱ   Passweg, Jakob ^y   Greinix, Hildegard ^z   Duarte, Rafael F ^aa   Kröger, Nicolaus ^v   Dreger, Peter ^w   Mohty, Mohamad ^m,n   Nagler, Arnon ^ab   Cesaro, Simone ^c   more..

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f European Bone Marrow Transplantation Group Data Office   (Italy)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k HENRI MONDOR HOSPITAL   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m HÔPITAL SAINT ANTOINE   (France)

ⁿ INSERM   (France)

^o BORDEAUX UNIVERSITY HOSPITAL   (France)

^p NANTES UNIVERSITY HOSPITAL   (France)

^q LILLE UNIVERSITY HOSPITAL   (France)

^r AIX MARSEILLE UNIVERSITY   (France)

^s CENTRE HOSPITALIER LYON SUD   (France)

^t UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^u UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^v UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^w UNIVERSITY OF HEIDELBERG   (Germany)

^x UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^y UNIVERSITY HOSPITAL BASEL   (Switzerland)

^z MEDICAL UNIVERSITY OF GRAZ   (Austria)

^aa HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^ab SHEBA MEDICAL CENTER   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DONOR; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; RECURRENCE FREE SURVIVAL; ADOLESCENT; ADVERSE EFFECTS; AGED; BLOOD; CHILD; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; ISOLATION AND PURIFICATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; VIROLOGY;

VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TISSUE DONORS;

EID: 84975726539     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.2405     Document Type: Article

References (46)

1. Balfour HH Jr, Sifakis F, Sliman JA, et al: Agespecific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis 208:1286-1293, 2013
2. Cohen JI: Epstein-Barr virus infection. N Engl J Med 343:481-492, 2000
3. Heslop HE: Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology (Am Soc Hematol Educ Program) 260-266, 2005
4. Styczynski J, Einsele H, Gil L, et al: Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: A comprehensive review of reported cases. Transpl Infect Dis 11:383-392, 2009
5. Sundin M, Le Blanc K, Ringdén O, et al: The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 91:1059-1067, 2006
6. Styczynski J, Reusser P, Einsele H, et al: Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: Guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43:757-770, 2009
7. Uhlin M, Wikell H, Sundin M, et al: Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 99:346-352, 2014
8. Curtis RE, Travis LB, Rowlings PA, et al: Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 94: 2208-2216, 1999
9. Styczynski J, Gil L, Tridello G, et al: Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: A study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis 57: 794-802, 2013
10. Schmidt-Hieber M, Labopin M, Beelen D, et al: CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: A report from the Acute Leukemia Working Party of EBMT. Blood 122:3359-3364, 2013
11. Ljungman P, Brand R, Einsele H, et al: Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: An EBMT megafile analysis. Blood 102:4255-4260, 2003
12. Ljungman P, Brand R, Hoek J, et al: Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: A study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis 59:473-481, 2014
13. Kröger N, Zabelina T, Krüger W, et al: Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 113:1060-1071, 2001
14. Boeckh M, Nichols WG: The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103:2003-2008, 2004
15. Kollman C, Howe CW, Anasetti C, et al: Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 98:2043-2051, 2001
16. Gratwohl A, Pasquini MC, Aljurf M, et al: One million haemopoietic stem-cell transplants: A retrospective observational study. Lancet Haematol 2: e91-e100, 2015
17. Glucksberg H, Storb R, Fefer A, et al: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18:295-304, 1974
18. Iacobelli S, EBMT Statistical Committee: Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 48:S1-S37, 2013 (suppl 1)
19. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer-Verlag, 2003
20. Zhang MJ, Fine J: Summarizing differences in cumulative incidence functions. Stat Med 27: 4939-4949, 2008
21. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
22. Pavletic SZ, Carter SL, Kernan NA, et al: Influence of T-cell depletion on chronic graft-versushost disease: Results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 106:3308-3313, 2005
23. Ratanatharathorn V, Logan B, Wang D, et al: Prior rituximab correlates with less acute graftversus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 145:816-824, 2009
24. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, et al: Efficacy of rituximab in the setting of steroidrefractory chronic graft-versus-host disease: A systematic review and meta-analysis. Biol Blood Marrow Transplant 15:1005-1013, 2009
25. Cutler C, Kim HT, Bindra B, et al: Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: Results of a phase 2 trial. Blood 122: 1510-1517, 2013
26. Storek J: Immunological reconstitution after hematopoietic cell transplantation: Its relation to the contents of the graft. Expert Opin Biol Ther 8: 583-597, 2008
27. Cutler C, Miklos D, Kim HT, et al: Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108:756-762, 2006
28. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al: Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 104:2603-2606, 2004
29. Ratanatharathorn V, Ayash L, Reynolds C, et al: Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9:505-511, 2003
30. Zaja F, Bacigalupo A, Patriarca F, et al: Treatment of refractory chronic GVHD with rituximab: A GITMO study. Bone Marrow Transplant 40:273-277, 2007
31. Coppoletta S, Tedone E, Galano B, et al: Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 17: 901-907, 2011
32. Dominietto A, Tedone E, Soracco M, et al: In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant 47: 101-106, 2012
33. Ratanatharathorn V, Carson E, Reynolds C, et al: Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 133:275-279, 2000
34. Olivieri J, Manfredi L, Postacchini L, et al: Consensus recommendations for improvement of unmet clinical needs: The example of chronic graftversus-host disease-A systematic review and metaanalysis. Lancet Haematol 2:e297-e305, 2015
35. Sarantopoulos S, Ritz J: Aberrant B-cell homeostasis in chronic GVHD. Blood 125:1703-1707, 2015
36. Iori AP, Torelli GF, De Propris MS, et al: B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 85:386-390, 2008
37. Michonneau D, Peffault de Latour R, Porcher R, et al: Influence of bone marrow graft B lymphocyte subsets on outcome after HLA-identical sibling transplants. Br J Haematol 145:107-114, 2009
38. Khouri IF, McLaughlin P, Saliba RM, et al: Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111:5530-5536, 2008
39. Crocchiolo R, Castagna L, El-Cheikh J, et al: Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Exp Hematol 39:892-896, 2011
40. Olkinuora H, von Willebrand E, Kantele JM, et al: The impact of early viral infections and graftversus-host disease on immune reconstitution following paediatric stem cell transplantation. Scand J Immunol 73:586-593, 2011
41. Cantoni N, Hirsch HH, Khanna N, et al: Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 16:1309-1314, 2010
42. Broers AE, van Der Holt R, van Esser JW, et al: Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-celldepleted stem cell transplantation. Blood 95:2240-2245, 2000
43. Ringdén O, Schaffer M, Le Blanc K, et al: Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers? Biol Blood Marrow Transplant 10:128-134, 2004
44. Snydman DR: Editorial commentary: The complexity of latent cytomegalovirus infection in stem cell donors. Clin Infect Dis 59:482-483, 2014
45. Stern M, de Wreede LC, Brand R, et al: Sensitivity of hematological malignancies to graftversus-host effects: An EBMT megafile analysis. Leukemia 28:2235-2240, 2014
46. Rouce RH, Louis CU, Heslop HE: Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol 21:476-481, 2014